Abstract:Dongmei Lu, 1 Maidina Abudouaini, 1, 2 Munire Kerimu, 2 Qiuping Leng, 1 Hongtao Wu, 1 Amar Aynazar, 1, 2 Zhiwei Zhong 1, 2 1 Center of Pulmonary and Critical Care Medicine, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, People's Republic of China; 2 Department of Public Health, Xinjiang Medical University, Urumqi, People's Republic of China Correspondence: Dongmei Lu, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, People's Republic of China, Tel +18997982968, Email Purpose: Severe community-acquired pneumonia (SCAP) is the leading cause of death among patients with infectious diseases worldwide. This study aimed to evaluate the effectiveness of metagenomic next-generation sequencing (mNGS) through detecting pathogens in bronchoalveolar lavage fluid (BALF) and identifying risk factors for recovery in SCAP patients. Patients and Methods: This prospective study recruited 158 SCAP patients admitted to respiratory intensive care unit that were randomly divided into control and study groups, with receiving conventional tests and the same conventional tests plus mNGS, respectively. The diagnostic efficiency of mNGS was evaluated by comparing with conventional tests. Furthermore, univariate and multivariate logistic regression analyses were performed to determine the independent risk factors for recovery in SCAP patients, and a nomogram prediction model was established based on these factors. Results: Within the study group, the pathogen detection rate was significantly higher with mNGS than that with conventional tests (84.81% vs 45.57%, P < 0.001), with a positive coincidence rate of 94.44%. Acinetobacter baumannii (21.52%, 17/79), Candida albicans (17.72%, 14/79), and Klebsiella pneumonia (15.19%, 12/79) were the top three common pathogens detected by mNGS. Of note, the improvement rate of patients in the study group was significantly higher than that in the control group. The further analysis revealed that the increased levels of interleukin-6, blood urea nitrogen, procalcitonin, the longer length of hospital stay, and bacterial infection were independent risk factors for recovery of SCAP patients, while mNGS detection status was a protective factor. The predictive model showed a good performance for the modeling and validation sets. Conclusion: Early mNGS exhibited a superior diagnostic efficiency to conventional tests in SCAP patients, which can reduce the risk of death in SCAP patients. Moreover, the clinical factors could also be used for the management and prognosis prediction of SCAP patients. Keywords: severe community-acquired pneumonia, metagenomic next-generation sequencing, pathogen, risk factor Infection is one of the major causes of death in patients with acute and critical illnesses. Especially, lower respiratory tract infections (LRTIs) are the most common infectious diseases worldwide, with a high mortality rate. 1,2 As estimated, there are about 10 million new cases of LRTIs in China each year. 3,4 Pneumonia, typically caused by LRTIs, is the leading cause of illness and death in adults, resulting in more than one million hospitalizations and a high intensive care unit (ICU) admission rate in the United States per year. 5 It is noteworthy that the mortality rate of severe community-acquired pneumonia (SCAP) is as high as 20–50%, and its high long-term morbidity is a serious challenge for ICU survivors, 6 with at least 3 million deaths worldwide in 2016. 1 In China, more than 20% of ICU patients are admitted due to sepsis with up to 35.5% 90-day mortality; actually, 68.2% of these sepsis cases are secondary to SCAP. 7 The high mortality is mainly attributable to the increased rate of treatment failure due to antibiotic resistance 8 and the lack of measures that can identify the relevant pathogens in a timely and accurate manner. 9,10 Due to fundamental diseases, invasive operations, compromised immune function, and overuse of wide-spectrum antibiotics in patients, especially elderly patients, the types of pathogens and antibiotic resistance in the lower respiratory tract have also been changing significantly and continuously, seriously affecting the clinical outcomes and threatening patients' health. Because of the low sensitivity, efficiency, and spectrum of detectable pathogens, current conventional microbial tests are always time-consuming and have a low positive detection rate of pathogens (~10%). Moreover, the detection of mixed infections and unknown pathogen infections is almost impossible with these conventional tests, resulting in the -Abstract Truncated-

Clinical Value of Metagenomics Next-Generation Sequencing in Bronchoalveolar Lavage Fluid for Patients with Severe Hospital-Acquired Pneumonia: A Nested Case–Control Study

Diagnostic Value of Metagenomic Next-Generation Sequencing for Multi-Pathogenic Pneumonia in HIV-Infected Patients.

Clinical Impact of Metagenomic Next-Generation Sequencing of Bronchoalveolar Lavage in the Diagnosis and Management of Pneumonia A Multicenter Prospective Observational Study

The diagnostic value of bronchoalveolar lavage fluid metagenomic next-generation sequencing in critically ill patients with respiratory tract infections

Effect of Metagenomic Next-Generation Sequencing on Clinical Outcomes in Adults with Severe Pneumonia Post-Cardiac Surgery: a Single-Center Retrospective Study

Diagnostic Value of Metagenomic Next-Generation Sequencing for the Detection of Pathogens in Bronchoalveolar Lavage Fluid in Ventilator-Associated Pneumonia Patients

Clinical Value of Sampling Time of Metagenomic Next-Generation Sequencing in Patients with Severe Pneumonia

Metagenomic Next-Generation Sequencing of Bronchoalveolar Lavage Fluid in Non-Severe and Severe Pneumonia Patients

Clinical Evaluation of Metagenomic Next-Generation Sequencing and Identification of Risk Factors in Patients with Severe Community-Acquired Pneumonia

The Application of Nanopore Targeted Sequencing for Pathogen Diagnosis in Bronchoalveolar Lavage Fluid of Patients with Pneumonia: a Prospective Multicenter Study.

Clinical application of metagenomic next‐generation sequencing technology in the diagnosis and treatment of pulmonary infection pathogens: A prospective single‐center study of 138 patients

Improving pulmonary infection diagnosis with metagenomic next-generation sequencing of bronchoalveolar lavage fluid

Clinical values of metagenomic next-generation sequencing in patients with severe pneumonia: a systematic review and meta-analysis

Advantages in pathogen detection of bronchoalveolar lavage fluid by metagenomic next-generation sequencing in severe pneumonia

Clinical Efficiency of Metagenomic Next-Generation Sequencing in Sputum for Pathogen Detection of Patients with Pneumonia According to Disease Severity and Host Immune Status

Metagenomic Next‑generation Sequencing of BALF for the Clinical Diagnosis of Severe Community‑acquired Pneumonia in Immunocompromised Patients: A Single‑center Study

Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Pulmonary Infectious Pathogens From Bronchoalveolar Lavage Samples

Metagenomic next generation sequencing of bronchoalveolar lavage fluids for the identification of pathogens in patients with pulmonary infection: A retrospective study

Applicability of Bronchoalveolar Lavage Fluid and Plasma Metagenomic Next-Generation Sequencing Assays in the Diagnosis of Pneumonia

Clinical application of bronchoalveolar lavage fluid metagenomics next-generation sequencing in cancer patients with severe pneumonia

Metagenomic Next-Generation Sequencing for Pathogens in Bronchoalveolar Lavage Fluid Improves the Survival of Patients with Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation.